Single‐center experience with self‐expanding transcatheter aortic valve system for symptomatic high‐risk patients with severe aortic regurgitation: One‐year outcomes

Abstract Aims To evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) for the treatment of aortic regurgitation (AR). Methods From September 2019 to February 2022, 62 patients who underwent transfemoral TAVI procedure for pure, symptomatic severe AR with the VitaFlow system were enrolled in the current study. The outcomes were assessed according to the Valve Academic Research Consortium 3 criteria. Procedural results and clinical outcomes for 1 year were analyzed. Results The mean age was 71.56 ± 7.34 years and 58.1% were male. The mean Society of Thoracic Surgeons score was 5.44 ± 3.22%. The device success rate was 79.0%. Only one patient was converted to open surgery. The in‐hospital mortality rate was 1.6%. The 1‐year all‐cause mortality rate was 6.5%. The new permanent pacemaker implantation rate was 29.0% in‐hospital and 30.7% at 1‐year follow‐up. The second valve implantation rate was 14.5%. No patient developed more than moderate paravalvular leakage during follow‐up. The mean ejection fraction improved from 54.05 ± 10.83% at baseline to 59.32 ± 8.70% ( p < 0.001 compared with baseline) at 12 months. Left ventricular end‐diastolic diameter decreased from 61.62 ± 5.58 mm at baseline to 55.20 ± 4.51 mm ( p < 0.001 compared with the baseline) at 12 months. Conclusions Transfemoral TAVI procedure shows efficacy in treating patients with severe pure native AR. The safety is improved with the development of the VitaFlow system.